Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968748 | 0.91 | KMT2A (0.57) | KMT2AMEN1LMNASMN1; SMN2PKM | |
| SCHEMBL963272 | 0.86 | SMN1; SMN2 (0.47) | KMT2AMEN1LMNASMN1; SMN2PKM | |
| SCHEMBL12915953 | 0.86 | SMN1; SMN2 (0.47) | KMT2AMEN1LMNASMN1; SMN2PKM | |
| SCHEMBL968750 | 0.86 | KMT2A (0.52) | KMT2AMEN1LMNASMN1; SMN2PKM | |
| SCHEMBL963690 | 0.85 | SMN1; SMN2 (0.44) | KMT2AMEN1LMNASMN1; SMN2PKM | |
| SCHEMBL10180839 | 0.85 | KMT2A (0.53) | KMT2AMEN1LMNASMN1; SMN2PKM | |
| SCHEMBL963584 | 0.84 | HDAC3 (0.42) | KMT2AMEN1LMNASMN1; SMN2PKM | |
| SCHEMBL964265 | 0.84 | KMT2A (0.78) | KMT2AMEN1LMNASMN1; SMN2PKM | |
| SCHEMBL963700 | 0.83 | KMT2A (0.54) | KMT2AMEN1LMNASMN1; SMN2PKM | |
| SCHEMBL964493 | 0.83 | ALDH1A1 (0.51) | KMT2AMEN1LMNASMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678168-B1 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1678168-A4 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
| EP-1678168-A2 | P70S6 KINASE MODULATORS AND METHOD OF USE | Exelixis, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005039506-A2 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EEF2K, RPS6KA3, MTOR | KMT2A 3420/4885MEN1 4049/4885LMNA 3817/4885 |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EEF2K, RPS6KA3, MTOR | KMT2A 3420/4885MEN1 4049/4885LMNA 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.